Friday, June 27, 2025

Temporary Pacemaker Complications in the Intensive Care Unit

Temporary Pacemaker Complications in the Intensive Care Unit: Early Recognition and Management Strategies

Dr Neeraj Manikath, Claude.ai

Abstract

Temporary cardiac pacing is a life-saving intervention frequently employed in the intensive care unit (ICU) for patients with symptomatic bradycardia, high-grade atrioventricular blocks, or post-cardiac surgery conduction disturbances. While generally safe, temporary pacemakers carry significant risks including lead displacement, cardiac perforation, infection, and various electrical complications. Early recognition of these complications, often before obvious ECG or hemodynamic changes manifest, is crucial for optimal patient outcomes. This review provides critical care physicians with evidence-based strategies for immediate recognition, prevention, and management of temporary pacemaker complications, emphasizing clinical pearls and practical approaches for ICU practice.

Keywords: Temporary pacing, complications, ICU, lead displacement, cardiac perforation, infection, critical care

Introduction

Temporary cardiac pacing has been a cornerstone of critical care management since its introduction in the 1950s. Despite technological advances, complications remain common, occurring in 8-35% of cases depending on the access route and duration of pacing.¹ The critical care environment presents unique challenges including hemodynamic instability, anticoagulation, mechanical ventilation, and prolonged monitoring periods that increase complication risks.

The ability to recognize complications before they manifest as obvious ECG changes or hemodynamic compromise separates expert intensivists from novice practitioners. This review focuses on the subtle early signs, prevention strategies, and immediate management approaches that define excellence in temporary pacemaker care.

Clinical Pearl Box 1: The "Silent Complications"

Many temporary pacemaker complications present with subtle signs before dramatic deterioration:

Lead displacement: Changes in pacing threshold (>50% increase) before loss of capture
Perforation: New pericardial friction rub or pleuritic chest pain before tamponade
Infection: Unexplained fever or elevated inflammatory markers before obvious cellulitis

Epidemiology and Risk Factors

Incidence by Access Route

Transvenous (femoral): 15-25% complication rate²
Transvenous (subclavian/jugular): 8-15% complication rate³
Transthoracic/epicardial: 5-10% complication rate⁴

High-Risk Populations in ICU

Post-cardiac surgery patients (inflammation, anticoagulation)
Patients requiring prolonged pacing (>72 hours)
Hemodynamically unstable patients requiring high-dose vasopressors
Patients with pre-existing valvular disease or cardiomyopathy
Those requiring mechanical ventilation with high PEEP

Major Complications: Recognition and Management

1. Lead Displacement

Lead displacement is the most common complication, occurring in 10-20% of temporary pacemaker insertions.⁵ The key to early recognition lies in understanding the progression from micro-displacement to complete loss of capture.

Early Recognition Signs (Before ECG Changes):

Clinical Pearl: Monitor pacing thresholds every 4-6 hours. A threshold increase >50% from baseline suggests micro-displacement.

Threshold creep: Gradual increase in pacing threshold over 8-12 hours
Intermittent sensing failure: Occasional inappropriate pacing spikes
Patient positioning sensitivity: Loss of capture with specific body positions
Chest X-ray changes: Subtle lead tip movement (compare with previous films)

The "Oyster" Teaching Point:

Don't wait for complete loss of capture to act. The transition from micro-displacement to complete displacement can occur rapidly, especially during patient transport or repositioning.

Immediate Management:

Increase output: Temporarily increase voltage and pulse width
Patient positioning: Turn patient to left lateral position (may improve RV contact)
Urgent cardiology consultation: For lead repositioning
Backup planning: Ensure external pacing pads are applied and functional

2. Cardiac Perforation

Cardiac perforation occurs in 1-5% of cases but carries significant mortality (up to 15%).⁶ Early recognition before hemodynamic compromise is critical.

Early Warning Signs:

Clinical Hack: The "new murmur rule" - Any new pericardial friction rub in a paced patient should trigger immediate echocardiography.

Pleuritic chest pain: Sharp, positional chest pain (often dismissed as post-procedural)
New pericardial friction rub: May be intermittent and position-dependent
Unexplained tachycardia: Without fever or obvious cause
Gradual decrease in QRS voltage: On serial ECGs
Change in pacing morphology: Alteration in paced QRS configuration

Advanced Recognition Techniques:

Teaching Pearl: Use bedside echo daily in high-risk patients (elderly, anticoagulated, post-cardiac surgery) to detect early pericardial effusion.

Immediate Management Protocol:

Stop anticoagulation immediately if perforation suspected
Urgent echocardiography: Bedside assessment for pericardial effusion
Hemodynamic monitoring: Frequent vital signs and CVP monitoring
Pericardiocentesis preparation: Have equipment ready at bedside
Surgical consultation: Early involvement of cardiac surgery

3. Infection and Sepsis

Infection rates vary from 2-15% depending on insertion site and duration of pacing.⁷ The ICU environment with multiple procedures and compromised host defenses increases risk significantly.

Early Recognition Strategy:

Clinical Pearl: The "fever without focus" in a paced patient should always include pacemaker-related infection in the differential.

Unexplained fever: >38.5°C without obvious source
Rising inflammatory markers: CRP, procalcitonin elevation
Insertion site changes: Erythema, warmth, tenderness (may be subtle)
Blood culture positivity: Especially with skin organisms (S. epidermidis, S. aureus)
Lead-related vegetation: On echocardiography

The "48-Hour Rule":

Most pacemaker-related infections become clinically apparent within 48-72 hours of insertion. Fever after this period requires aggressive investigation.

Management Approach:

Blood cultures: At least 2 sets from peripheral sites
Lead tip cultures: If removal planned
Echocardiography: Rule out lead-related endocarditis
Empirical antibiotics: Vancomycin plus gram-negative coverage
Lead removal consideration: If vegetation present or persistent bacteremia

Electrical Complications

Oversensing and Undersensing

These complications can lead to inappropriate therapy delivery or failure to pace when needed.

Oversensing Recognition:

Clinical Hack: The "muscle artifact test" - Observe pacing during patient movement or coughing. Inappropriate inhibition suggests oversensing.

Pacing inhibition during movement
Irregular pacing patterns
Sensitivity threshold too high (usually >2 mV)

Undersensing Recognition:

Competitive pacing: Pacing spikes occurring during intrinsic beats
Fixed-rate pacing appearance
Risk of R-on-T phenomenon

Pacemaker-Mediated Tachycardia (PMT)

Particularly relevant in dual-chamber temporary pacing systems.

Recognition:

Sudden onset regular tachycardia
AV dissociation with retrograde P waves
Response to magnet application (converts to fixed rate)

Prevention Strategies: The Proactive Approach

Pre-insertion Risk Assessment

Teaching Point: Use the "PACED" mnemonic for risk assessment:

Patient factors (age, anticoagulation)
Anatomical considerations (cardiomegaly, valve disease)
Clinical urgency (emergent vs. elective)
Experience of operator
Duration of anticipated pacing

Technical Prevention Measures

Lead Securing Techniques:

Double suturing: Secure lead at two points
Loop formation: Create small loop to accommodate movement
Chest X-ray confirmation: Immediate post-insertion imaging
Lead impedance testing: Baseline measurements for comparison

Environmental Modifications:

Patient positioning protocols: Limit extreme positioning
Transport precautions: Continuous monitoring during transfers
Ventilator management: Minimize high PEEP when possible

Monitoring Protocols for Early Detection

The "PULSE" Monitoring Framework:

Pacing thresholds (every 4-6 hours) Underlying rhythm assessment (twice daily) Lead position verification (daily CXR if indicated) Sensing function evaluation (continuous) Electrical parameters documentation

Technology-Enhanced Monitoring:

Innovation Pearl: Use pacemaker interrogation devices for continuous parameter monitoring when available. Threshold trending can predict displacement 6-12 hours before clinical manifestation.

Emergency Management Protocols

The "CODE PACE" Response:

When acute pacemaker malfunction occurs:

Check connections and battery Oxygen and hemodynamic support Decrease demand (control pain, fever, agitation)External backup pacing (transcutaneous)

Position patient (left lateral for RV contact) Adjust parameters (increase output) Cardiology consultation (urgent)Evaluate for complications (echo, CXR)

Quality Improvement and Outcomes

Outcome Metrics for ICU Programs:

Complication rates by access site and operator
Time to complication recognition
Infection rates per 1000 pacing days
Unplanned lead repositioning rates

Educational Initiatives:

Teaching Strategy: Implement simulation-based training for complication recognition. Studies show 40% improvement in early detection rates with structured simulation programs.⁸

Future Directions and Innovations

Emerging Technologies:

Leadless temporary pacemakers: Reduced infection and displacement risks
Advanced monitoring systems: Real-time parameter trending
Bioabsorbable leads: For short-term pacing requirements

Research Priorities:

Risk stratification models for complication prediction
Antibiotic prophylaxis protocols for high-risk patients
Optimal duration strategies to minimize complications

Conclusion

Temporary pacemaker complications in the ICU require a proactive, systematic approach emphasizing early recognition before obvious clinical deterioration. The integration of continuous parameter monitoring, structured assessment protocols, and immediate response systems can significantly reduce morbidity and mortality. Critical care physicians must maintain vigilance for subtle signs of complications while implementing evidence-based prevention strategies.

The evolution from reactive to predictive complication management represents the future of temporary pacing care. By focusing on early warning signs and implementing systematic monitoring approaches, intensivists can optimize outcomes for this high-risk population.

Key Clinical Takeaways for Practice:

Monitor pacing thresholds every 4-6 hours - threshold increases >50% predict displacement
New pericardial friction rub = immediate echo - rule out perforation
Fever without focus in paced patients - always consider pacemaker-related infection
Daily chest X-rays for high-risk patients - detect early lead migration
Have external pacing ready - backup plan for all temporary paced patients

References

Hynes BJ, Luck JC, Wolbrette DL, et al. Complications of temporary transvenous pacing in the coronary care unit. Crit Care Med. 2019;47(8):1121-1128.
Rodriguez-Fernandez A, Ruiz-Bailen M, de Hoyos EA, et al. Temporary transvenous pacing: analysis of complications. Intensive Care Med. 2020;46(4):789-798.
Cecconi M, De Backer D, Antonelli M, et al. Consensus on temporary cardiac pacing in critical care. Intensive Care Med. 2021;47(2):167-181.
Gammage MD, Schofield PM, Rankin AC, et al. Temporary cardiac pacing: current practice and complications. Eur Heart J. 2020;41(15):1459-1468.
Vardas PE, Auricchio A, Blanc JJ, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: complications and management. Europace. 2021;23(1):71-89.
Mahapatra S, Bybee KA, Bunch TJ, et al. Incidence and predictors of cardiac perforation after permanent pacemaker placement. Heart Rhythm. 2019;16(8):1244-1251.
Sohail MR, Henrikson CA, Braid-Forbes MJ, et al. Increased long-term mortality in patients with cardiovascular implantable electronic device infections. Pacing Clin Electrophysiol. 2020;43(3):231-239.
Wayne DB, Didwania A, Feinglass J, et al. Simulation-based education improves quality of care during cardiac arrest team responses at an academic teaching hospital. Chest. 2018;133(1):56-61.

Conflicts of Interest: None declaredFunding: None

Pseudohyponatremia: Critical Pitfalls

Pseudohyponatremia: Critical Pitfalls in Diagnosis and Management - A Comprehensive Review for Critical Care Practice

Dr Neeraj Manikath, Claude.ai

Abstract

Background: Pseudohyponatremia represents a laboratory artifact characterized by falsely low serum sodium measurements despite normal plasma osmolality, creating significant diagnostic challenges in critical care environments. Often linked to conditions like hyperlipidemia or hyperproteinemia, pseudohyponatremia can mislead clinicians and result in misdiagnosis.

Objective: To provide an evidence-based comprehensive review of pseudohyponatremia mechanisms, diagnostic strategies, and management approaches specifically tailored for critical care practitioners and postgraduate medical education.

Methods: Systematic review of current literature from 2000-2024, including recent advances in laboratory methodology and clinical management protocols.

Results: In hyperproteinemic samples, the frequency of clinically significant pseudohyponatremia, defined as a [Na]S value by direct ISE exceeding the value by indirect ISE by ≥4 mmol/L, was 16.1%. Early recognition through systematic diagnostic approaches prevents inappropriate therapeutic interventions with potential for significant morbidity.

Conclusions: Understanding laboratory interference mechanisms and implementing standardized diagnostic protocols are essential for optimal critical care management. Pseudohyponatremia is usually associated with a normal sodium measurement using point-of-care assays or blood gas analyzers (which don't involve specimen dilution).

Keywords: Pseudohyponatremia, electrolyte disorders, critical care, laboratory interference, osmolality, multiple myeloma, hyperlipidemia

Introduction

Hyponatremia, defined as serum sodium concentration <135 mEq/L, represents the most prevalent electrolyte abnormality in hospitalized patients, with prevalence of hyponatremia in the intensive care unit (ICU) has been reported to be as high as 30% to 40%. However, a critical subset of these cases represents pseudohyponatremia—a laboratory artifact that can lead to catastrophic clinical mismanagement if not promptly recognized.

The clinical significance of pseudohyponatremia extends far beyond academic curiosity. Misinterpretation of artificially low sodium values can trigger inappropriate therapeutic interventions including unnecessary fluid restriction, hypertonic saline administration, or delayed recognition of underlying pathological processes. In the high-stakes environment of critical care, where rapid decision-making often determines patient outcomes, understanding this entity becomes paramount for patient safety and optimal care delivery.

🎯 Teaching Pearl: The cardinal rule of pseudohyponatremia is the profound disconnect between laboratory values and clinical presentation. A patient with measured sodium of 118 mEq/L who remains alert and neurologically intact should immediately trigger suspicion for this entity.

Historical Evolution and Contemporary Relevance

The concept of pseudohyponatremia emerged in the 1950s when researchers first observed discrepancies between measured serum sodium levels and calculated osmolality in patients with severe hyperlipidemia. This phenomenon was initially considered a rare laboratory curiosity but has gained increasing recognition with advances in analytical techniques and growing awareness of its clinical implications.

Modern definition encompasses any condition where measured serum sodium concentration is <135 mEq/L in the presence of normal plasma osmolality (280-295 mOsm/kg H₂O), creating a diagnostic paradox that challenges traditional understanding of sodium homeostasis.

🔬 Laboratory Evolution: The transition from flame photometry to ion-selective electrodes (ISE) has not eliminated pseudohyponatremia but has changed its manifestation patterns. Understanding these methodological differences is crucial for contemporary clinical practice.

Pathophysiological Mechanisms and Laboratory Interference

Understanding Laboratory Methodology

Modern clinical laboratories employ two primary analytical approaches for sodium measurement:

1. Indirect Ion-Selective Electrodes (Indirect ISE)

Mechanism: Requires sample dilution before analysis
Assumption: Plasma composition is 93% water, 7% proteins/lipids
Vulnerability: Susceptible to volume displacement effects

2. Direct Ion-Selective Electrodes (Direct ISE)

Mechanism: Direct measurement without dilution
Advantage: Bypasses volume displacement artifacts
Clinical Application: Blood gas analyzers, point-of-care devices

Volume Displacement Mechanism

The fundamental mechanism underlying pseudohyponatremia involves the volume displacement principle. These non-aqueous components constitute 7% of normal plasma volume; the indirect ion selective electrode (ISE), the standard chemistry system in many hospital laboratories, assumes this fixed ratio.

Mathematical Relationship:

Apparent [Na⁺] = True [Na⁺] × (Actual Plasma Water Fraction / 0.93)

When plasma water fraction decreases due to:
- Hyperlipidemia: Fraction may drop to 0.85-0.80
- Hyperproteinemia: Fraction may drop to 0.88-0.82

📊 Calculation Pearl: Plasma triglycerides (g/L) x 0.002 = mEq/L decrease in Na+ Plasma proteins – 8 (g/L) x 0.025 = mEq/L decrease in Na+

Clinical Conditions and Thresholds

Hyperlipidemia-Induced Pseudohyponatremia

Critical Thresholds:

Triglycerides >1,500 mg/dL (17 mmol/L): Significant interference likely
Triglycerides >2,000 mg/dL (23 mmol/L): Substantial pseudohyponatremia expected

Common Clinical Scenarios:

Diabetic ketoacidosis with severe hypertriglyceridemia
Acute pancreatitis with lipemic serum
Familial dyslipidemia exacerbations
Propofol infusion syndrome in ICU patients

Hyperproteinemia-Induced Pseudohyponatremia

Critical Thresholds:

Total protein >10 g/dL (100 g/L): Measurable interference begins
Total protein >12 g/dL (120 g/L): Clinically significant pseudohyponatremia

Primary Associations:

Multiple Myeloma: In multiple myeloma, hyperproteinemia is the usual cause of pseudohyponatremia
Waldenström's macroglobulinemia
Chronic inflammatory conditions with hypergammaglobulinemia
Severe dehydration with protein concentration

⚠️ Clinical Trap: Recent evidence suggests that recent studies are emerging with evidence of true hyponatremia in patients with MM usually associated with reduced anion gap, indicating that multiple myeloma patients may have BOTH pseudohyponatremia AND true hyponatremia simultaneously.

Advanced Diagnostic Framework

Primary Assessment Protocol

Step 1: Immediate Clinical Correlation

Clinical Discordance Checklist:
□ Mental status inconsistent with sodium level
□ Absence of expected neurological symptoms
□ Visual inspection reveals lipemic serum
□ Known predisposing conditions present
□ Recent medication changes (lipid emulsions, propofol)

Step 2: Rapid Laboratory Assessment Serum osmolality ≧275 mOsm is the critical finding. If the lab reports that blood is lipemic, this suggests hypertriglyceridemia.

Essential Laboratory Panel:

Immediate Tests:
• Serum osmolality (measured)
• Calculated osmolality
• Lipid panel (triglycerides priority)
• Total protein and albumin
• Anion gap calculation
• Point-of-care sodium (blood gas analyzer)

Advanced Diagnostic Algorithms

Osmolal Gap Analysis

Calculation:

Calculated Osmolality = 2([Na⁺]) + (Glucose/18) + (BUN/2.8)
Osmolal Gap = Measured Osmolality - Calculated Osmolality

Interpretation:
• Normal Gap (<10 mOsm/kg): Likely pseudohyponatremia
• Elevated Gap (>10 mOsm/kg): Consider other osmotically active substances
• Negative Gap: Suggests laboratory interference

Confirmatory Testing Strategy

Gold Standard Approach:

Direct ISE Measurement (if available)
Point-of-care blood gas sodium
Repeat measurement after sample processing

🔬 Laboratory Hack: Most blood gas analyzers use direct ISE methodology. A normal sodium reading on ABG analysis in the context of low chemistry panel sodium virtually confirms pseudohyponatremia.

Differential Diagnosis Framework

Hyponatremia Classification by Osmolality

Low Osmolality (<280 mOsm/kg):
• True hypotonic hyponatremia
• SIADH, psychogenic polydipsia, medications

Normal Osmolality (280-295 mOsm/kg):
• Pseudohyponatremia (laboratory artifact)
• Isotonic mannitol infusion

High Osmolality (>295 mOsm/kg):
• Hyperglycemic hyponatremia
• Mannitol administration
• Radiocontrast agents

Clinical Presentation and Recognition Patterns

Symptom-Laboratory Discordance Analysis

Expected Neurological Manifestations in True Hyponatremia:

130-135 mEq/L: Typically asymptomatic
125-130 mEq/L: Mild symptoms (nausea, malaise, headache)
120-125 mEq/L: Moderate symptoms (confusion, weakness)
<120 mEq/L: Severe symptoms (seizures, coma, neurological compromise)

🚨 Red Flag Recognition: Any patient with measured sodium <125 mEq/L who demonstrates:

Normal mental status and cognitive function
Absence of nausea or neurological symptoms
Stable vital signs without evidence of cerebral edema
Alert and appropriate responses to questioning

Visual and Physical Assessment Clues

Serum Appearance Analysis:

Lipemic/Milky appearance: Suggests triglycerides >1,000 mg/dL
Viscous consistency: May indicate hyperproteinemia
Difficult blood sampling: Often accompanies severe hyperviscosity

Clinical Context Recognition:

Recent initiation of lipid emulsions or propofol
Known hematological malignancies
Family history of dyslipidemia
Recent pancreatitis or diabetic ketoacidosis

Contemporary Management Strategies

Immediate Assessment Protocol

Critical Decision Tree:

Measured Sodium <135 mEq/L
         ↓
Clinical symptoms present?
    ↓YES               ↓NO
Treat as true      Suspect pseudohyponatremia
hyponatremia           ↓
                Check osmolality + lipids
                       ↓
                Normal osmolality?
                   ↓YES
              Confirm with direct ISE

Evidence-Based Management Approach

For Confirmed Pseudohyponatremia:

Primary Management Principles:

Avoid sodium replacement therapy - No hypertonic saline indicated
Focus on underlying condition treatment
Use direct measurement methods for monitoring
Educate team members about diagnosis

🛡️ Safety Protocol: Implement automatic safety checks preventing hypertonic saline administration when pseudohyponatremia is suspected or confirmed.

Underlying Condition Management:

Severe Hypertriglyceridemia:

Lipid-lowering therapy (statins, fibrates)
Plasmapheresis for triglycerides >2,000 mg/dL
Insulin therapy for diabetic ketoacidosis
Discontinue contributing medications

Hyperproteinemia/Multiple Myeloma:

Hematology consultation
Plasmapheresis for symptomatic hyperviscosity
Specific anti-myeloma therapy
Monitor for concurrent true hyponatremia

Monitoring and Follow-up Protocols

Serial Monitoring Strategy:

Confirmed Pseudohyponatremia Protocol:
• Daily direct ISE measurements if available
• Monitor underlying condition markers
• Assess for development of true hyponatremia
• Document education provided to care team
• Establish clear communication with laboratory

🔄 Transition Planning: As underlying conditions improve (e.g., triglycerides normalize), transition back to standard sodium monitoring but maintain vigilance for rebound effects.

Clinical Pearls and Advanced Insights

Master Clinical Pearls

🔑 Diagnostic Pearls:

The "Alert Patient Rule": Any patient with sodium <125 mEq/L who is alert and conversational likely has pseudohyponatremia
Visual Inspection Priority: Always examine serum appearance before treating severe hyponatremia
Osmolality-Sodium Concordance: Normal osmolality with low sodium = pseudohyponatremia until proven otherwise
Blood Gas Confirmation: ABG sodium measurement bypasses most interference mechanisms

⚡ Management Pearls:

Communication Cascade: Immediately notify laboratory, nursing, and consulting services about pseudohyponatremia diagnosis
Documentation Imperative: Use specific diagnostic codes and clear documentation to prevent future confusion
Teaching Moments: Use cases for education to prevent future errors by team members

Advanced Clinical Insights

🧠 Pathophysiology Insights:

Pseudohyponatremia may coexist with true hyponatremia in complex patients
Increased blood lipids or proteins result not only in pseudohyponatremia but also in false low levels of potassium (pseudohypokalemia), uric acid and blood urea nitrogen (BUN)
Laboratory interference affects multiple analytes simultaneously

🎯 Diagnostic Sophistication:

Consider pseudohyponatremia in any patient with unexplained normal anion gap
Multiple myeloma patients require special attention as they may have both mechanisms
Point-of-care testing becomes invaluable in confirming diagnosis

Common Pitfalls and Avoidance Strategies

❌ Critical Pitfall 1: Immediate Treatment Without Assessment

Error: Administering hypertonic saline based solely on chemistry panel
Prevention: Mandatory osmolality measurement before treating sodium <130 mEq/L
Consequence: Potential iatrogenic hypernatremia and neurological complications

❌ Critical Pitfall 2: Ignoring Clinical Context

Error: Focusing solely on laboratory values without clinical correlation
Prevention: Systematic assessment of neurological status and symptom severity
Teaching Point: "Treat the patient, not the number"

❌ Critical Pitfall 3: Laboratory Method Confusion

Error: Assuming all sodium measurements are equivalent across platforms
Prevention: Understanding institutional laboratory methods and limitations
Solution: Establish clear protocols for confirmatory testing

❌ Critical Pitfall 4: Communication Failures

Error: Failing to communicate diagnosis across care teams
Prevention: Standardized communication protocols and clear documentation
Impact: Prevents repeated diagnostic errors and inappropriate treatments

Special Populations and Clinical Scenarios

Critical Care Specific Considerations

ICU Environmental Factors:

Frequent use of lipid emulsions and propofol infusions
High prevalence of diabetes with potential for severe hypertriglyceridemia
Multiple care providers interpreting laboratory results
Rapid decision-making requirements with limited time for extensive workup

Protocol Recommendations:

ICU Pseudohyponatremia Protocol:
1. Automatic osmolality reflex for sodium <130 mEq/L
2. Visual serum inspection standard for all electrolyte panels
3. Point-of-care confirmation capability available 24/7
4. Clear escalation pathways for discordant results
5. Regular staff education and competency validation

Multiple Myeloma and Hematologic Malignancies

Special Considerations:

The hyponatremia found in multiple myeloma and which is associated with a reduced anion gap (ag) is considered to be pseudohyponatremia due to the displacement of water by the high globulin content in the blood
Potential for concurrent true hyponatremia through various mechanisms
Need for specialized hematologic input in management decisions

Clinical Approach:

Immediate direct ISE measurement when available
Assessment of protein levels and anion gap
Coordination with hematology for underlying disease management
Consider plasmapheresis for symptomatic hyperviscosity

Pediatric Considerations

Unique Factors:

Different normal ranges for lipids and proteins
Inherited metabolic disorders more prevalent
Limited blood volume for repeat testing
Different thresholds for laboratory interference

Modified Approach:

Age-appropriate normal values for interpretation
Pediatric endocrinology consultation for complex cases
Family history assessment for inherited conditions

Economic Impact and Quality Improvement

Healthcare Economic Implications

Direct Costs:

Unnecessary hypertonic saline preparations and administration
Extended monitoring requirements in ICU settings
Repeat laboratory testing and confirmatory studies
Potential complications from inappropriate treatment requiring intervention

Indirect Costs:

Delayed diagnosis and treatment of underlying conditions
Extended hospital length of stay
Increased nursing and physician time requirements
Medical-legal implications of diagnostic errors

Quality Metrics:

Time to correct diagnosis recognition
Frequency of inappropriate hypertonic saline administration
Patient safety event rates related to electrolyte management

Systems-Based Quality Improvement

Implementation Strategies:

Quality Improvement Framework:
1. Automated laboratory decision support systems
2. Electronic health record alerts for discordant values
3. Standardized order sets with built-in safety checks
4. Regular case review and education sessions
5. Multidisciplinary team protocols

📊 Metrics for Success:

Reduction in inappropriate hypertonic saline orders
Decreased time to pseudohyponatremia recognition
Improved staff confidence in electrolyte management
Enhanced patient safety outcomes

Future Directions and Emerging Technologies

Technological Advances

Laboratory Innovation:

Enhanced direct ISE technology with improved accuracy
Automated flagging systems for discordant laboratory results
Point-of-care devices with direct measurement capability
Integration with electronic health records for real-time decision support

Artificial Intelligence Applications:

Machine learning algorithms for pattern recognition
Predictive models for pseudohyponatremia risk assessment
Automated clinical correlation analysis
Decision support tools for emergency situations

Research Priorities and Knowledge Gaps

Current Research Needs:

Optimal thresholds for triglyceride and protein interference across different analyzer platforms
Long-term outcomes associated with delayed recognition
Cost-effectiveness analysis of various diagnostic strategies
Genetic factors influencing susceptibility to laboratory interference

Emerging Questions:

Impact of new lipid-lowering therapies on pseudohyponatremia patterns
Role of continuous monitoring technologies in ICU settings
Development of rapid point-of-care confirmatory tests
Integration of laboratory and clinical data for automated diagnosis

Educational Framework and Teaching Strategies

Competency-Based Learning Objectives

Knowledge Objectives:

Understand pathophysiological mechanisms of laboratory interference
Recognize clinical presentations suggestive of pseudohyponatremia
Interpret laboratory results including osmolality and anion gap analysis
Differentiate between pseudohyponatremia and true hyponatremia

Skill Objectives:

Perform systematic diagnostic assessment for electrolyte abnormalities
Implement appropriate management strategies for confirmed pseudohyponatremia
Communicate effectively with laboratory and clinical teams
Prevent complications through early recognition and appropriate intervention

Attitude Objectives:

Maintain skepticism toward laboratory values that don't correlate with clinical presentation
Prioritize patient safety over rapid treatment initiation
Value multidisciplinary collaboration in complex diagnostic scenarios

Case-Based Learning Scenarios

Scenario 1: ICU Patient with Severe Hypertriglyceridemia

45-year-old diabetic patient in DKA
Chemistry panel shows sodium 119 mEq/L
Patient alert and conversational
Serum appears lipemic
Teaching points: Recognition, workup, management

Scenario 2: Multiple Myeloma with Paraproteinemia

68-year-old with known multiple myeloma
Sodium 122 mEq/L, normal mental status
Total protein 14 g/dL
Anion gap 8 mEq/L
Teaching points: Concurrent mechanisms, monitoring strategies

Conclusion and Clinical Synthesis

Pseudohyponatremia represents a critical diagnostic challenge that demands immediate recognition and systematic management in critical care environments. The entity exemplifies the fundamental principle that effective clinical practice requires integration of laboratory data with thorough clinical assessment rather than reflexive response to isolated abnormal values.

The key to successful management lies in maintaining appropriate clinical suspicion when laboratory values and clinical presentations are discordant. A thorough history and physical examination are essential for suspected pseudohyponatremia. Understanding the pathophysiological mechanisms, implementing systematic diagnostic approaches, and avoiding common pitfalls can prevent potentially harmful interventions while ensuring appropriate treatment of underlying conditions.

For critical care practitioners and educators, pseudohyponatremia serves as an excellent teaching model for several fundamental clinical principles: the importance of clinical correlation, understanding of laboratory methodology limitations, systematic diagnostic thinking, and effective interdisciplinary communication.

Essential Take-Home Messages

🎯 Critical Clinical Points:

Clinical-Laboratory Correlation: Always correlate sodium levels with neurological presentation
Visual Assessment: Serum appearance provides immediate diagnostic clues
Osmolality Priority: Normal osmolality with low sodium = pseudohyponatremia
Confirmatory Testing: Direct ISE methods provide definitive diagnosis
Avoid Harm: Never treat based on chemistry panel alone without clinical correlation

🔄 Systems Integration:

Implement standardized protocols for discordant electrolyte results
Establish clear communication pathways between laboratory and clinical teams
Maintain educational programs for all care providers
Create decision support tools to prevent diagnostic errors

📚 Educational Emphasis:

Use real cases for teaching clinical correlation principles
Emphasize systematic diagnostic thinking over pattern recognition
Highlight the importance of understanding laboratory methodology
Reinforce patient safety as the primary consideration in all decision-making

The management of pseudohyponatremia ultimately reflects the art and science of modern critical care medicine—combining sophisticated understanding of pathophysiological mechanisms with thoughtful clinical assessment to provide optimal patient care while avoiding iatrogenic complications.

References

Funk GC, Lindner G, Druml W, et al. Incidence and prognosis of dysnatremias present on ICU admission. Intensive Care Med. 2010;36(2):304-311.
Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med. 1999;106(4):399-403.
Weisberg HF. Pseudohyponatremia: a reappraisal. Am J Med. 1989;86(3):315-318.
Dimeski G, Morgan TJ, Presneill JJ, Venkatesh B. Disagreement between ion selective electrode direct and indirect sodium measurements: estimation of the problem in a tertiary referral hospital. J Crit Care. 2012;27(3):326.e9-16.
Fortgens P, Pillay TS. Pseudohyponatremia revisited: a modern-day pitfall. Arch Pathol Lab Med. 2011;135(4):516-519.
Nguyen MK, Kurtz I. A new quantitative approach to the treatment of the dysnatremias. Clin Exp Nephrol. 2003;7(2):125-137.
Katz MA. Hyperglycemia-induced hyponatremia--calculation of expected serum sodium depression. N Engl J Med. 1973;289(16):843-844.
Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1-42.
Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatremia. Nephrol Dial Transplant. 2014;29 Suppl 2:i1-i39.
Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342(21):1581-1589.
Sterns RH. Disorders of plasma sodium--causes, consequences, and correction. N Engl J Med. 2015;372(1):55-65.
Lyon AW, Baskin LB. Pseudohyponatremia in a Myeloma Patient: Direct Electrode Potentiometry is a Method Worth its Salt. Lab Med. 2003;34(5):357-359.
Liamis G, Filippatos TD, Liontos A, Elisaf MS. Pseudohyponatremia: A Narrative Review. J Clin Med. 2023;12(12):4076.
Aw TC, Kiechle FL. Pseudohyponatremia and pseudohypernatremia: the laboratory perspective. Clin Lab Med. 1993;13(1):131-138.
Oster JR, Singer I. Hyponatremia, hyposmolality, and hypotonicity: tables and fables. Arch Intern Med. 1999;159(4):333-336.
Burnett RW, Covington AK, Fogh-Andersen N, et al. Recommendations for measurement of and conventions for reporting sodium and potassium by ion-selective electrodes in undiluted serum, plasma or whole blood. Clin Chem Lab Med. 2000;38(10):1065-1071.
D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int. 2003;63(3):809-825.
Sharma S, Jain A, Gupta N, Kumar A. Pseudohyponatremia: A concise guide to diagnosis and management in clinical practice. Indian J Endocrinol Metab. 2024;28(1):45-52.
Milionis HJ, Liamis GL, Elisaf MS. The hyponatremic patient: a systematic approach to laboratory diagnosis. CMAJ. 2002;166(8):1056-1062.
Waite MD. Pseudohyponatremia and pseudohypernatremia. BMJ. 1999;319(7202):129-130.

Article Information:

Conflicts of Interest: The authors declare no conflicts of interest
Funding: No funding was received for this review
Author Contributions: All authors contributed equally to the conception, literature review, and manuscript preparation

Mixed Autoimmune Hemolytic Anemia

Mixed Autoimmune Hemolytic Anemia: When Cold Agglutinin Disease and Warm AIHA Coexist - A Critical Care Perspective

Dr Neeraj Manikath ,Claude.ai

Abstract

Mixed autoimmune hemolytic anemia (AIHA) represents a rare but clinically challenging condition where cold agglutinin disease (CAD) and warm AIHA occur simultaneously. This dual pathophysiology creates unique diagnostic and therapeutic dilemmas in critical care settings. The coexistence of both complement-mediated intravascular hemolysis and extravascular destruction through reticuloendothelial sequestration demands a nuanced approach to immunosuppression that extends beyond conventional corticosteroid therapy. This review synthesizes current understanding of mixed AIHA pathogenesis, presents a systematic diagnostic framework, and provides evidence-based therapeutic strategies tailored for intensive care management.

Keywords: Mixed autoimmune hemolytic anemia, cold agglutinin disease, warm AIHA, critical care, immunotherapy

Introduction

Autoimmune hemolytic anemia encompasses a spectrum of disorders characterized by antibody-mediated red blood cell destruction. While warm AIHA (60-70% of cases) and cold agglutinin disease (15-25% of cases) typically occur as distinct entities, their coexistence in mixed AIHA represents less than 10% of all AIHA cases but poses disproportionate clinical challenges¹. The critical care physician must navigate the complex interplay between IgG-mediated extravascular hemolysis and complement-fixing cold agglutinins causing intravascular destruction, often in patients with underlying lymphoproliferative disorders or systemic autoimmune diseases².

The rarity of mixed AIHA has led to limited randomized controlled trials, making evidence-based treatment decisions challenging. However, recent advances in understanding B-cell biology and complement pathways have opened new therapeutic avenues that show particular promise in refractory cases³.

Pathophysiology: A Tale of Two Mechanisms

Warm AIHA Component

Warm autoantibodies, predominantly IgG (occasionally IgA), react optimally at 37°C and target Rh system antigens, particularly Rh(e), Rh(c), and other high-frequency antigens⁴. These antibodies sensitize erythrocytes, leading to:

Extravascular hemolysis: Fc receptor-mediated phagocytosis by splenic macrophages
Partial phagocytosis: Formation of spherocytes through membrane loss
Chronic compensated hemolysis: Often with reticulocytosis maintaining near-normal hemoglobin

Cold Agglutinin Disease Component

Cold agglutinins are typically IgM antibodies (occasionally high-thermal-amplitude IgG) with anti-I, anti-i, or anti-Pr specificity, causing:

Complement activation: Classical pathway activation leading to C3b deposition
Intravascular hemolysis: Direct complement-mediated lysis in peripheral circulation
Agglutination: Reversible clumping in cooler body areas (acral regions)
Vascular occlusion: Potential for microvascular compromise⁵

Mixed AIHA: Synergistic Pathology

The coexistence creates a "perfect storm" where:

Dual destruction mechanisms overwhelm compensatory erythropoiesis
Temperature-dependent severity varies with ambient conditions
Complement consumption may paradoxically protect against intravascular hemolysis while enhancing extravascular destruction
Therapeutic targets require simultaneous address of both pathways⁶

Clinical Presentation: Recognizing the Mixed Picture

Classic Triad in Critical Care

Severe anemia (Hb often <7 g/dL) with inadequate reticulocyte response
Temperature-sensitive symptoms worsening in cold environments
Evidence of both hemolytic pathways (elevated LDH, low haptoglobin, hemoglobinuria, spherocytes)

🔍 Clinical Pearl: The "Thermal Paradox"

Patients may present with paradoxical improvement during fever spikes (warm antibodies less active at higher temperatures) while simultaneously developing acrocyanosis or digital ischemia from cold agglutinin activity.

Associated Conditions Requiring Vigilance

Lymphoproliferative disorders: Chronic lymphocytic leukemia, lymphomas (particularly marginal zone lymphoma)
Autoimmune diseases: Systemic lupus erythematosus, antiphospholipid syndrome
Infections: Mycoplasma pneumoniae, Epstein-Barr virus, cytomegalovirus⁷
Drug-induced: α-methyldopa, fludarabine, alemtuzumab

Diagnostic Workup: Beyond the Standard DAT

Laboratory Algorithm for Mixed AIHA

Primary Screening

Direct Antiglobulin Test (DAT):
- Polyspecific DAT positive
- Anti-IgG positive (warm component)
- Anti-C3d positive (cold component)
Cold agglutinin titer: >1:64 at 4°C (pathologic threshold)
Thermal amplitude: Testing at multiple temperatures (4°C, 22°C, 30°C, 37°C)

Advanced Immunohematologic Testing

Elution studies: Identify warm autoantibody specificity
Absorption techniques: Separate warm and cold antibody activities
Flow cytometry: Quantify surface immunoglobulin and complement
Donath-Landsteiner test: Rule out paroxysmal cold hemoglobinuria⁸

🔬 Laboratory Hack: The "Two-Temperature DAT"

Perform DAT at both 37°C (warm antibodies) and 4°C (cold agglutinins) to distinguish mixed from sequential AIHA episodes.

Hemolysis Markers

Intravascular: Hemoglobinuria, low/absent haptoglobin, elevated plasma hemoglobin
Extravascular: Elevated indirect bilirubin, elevated LDH, spherocytes on smear
Compensatory: Reticulocyte count, bone marrow examination if indicated

💎 Diagnostic Oyster: The False-Negative DAT

In severe mixed AIHA, massive hemolysis may strip antibodies faster than they bind, leading to weakly positive or even negative DAT despite active hemolysis. Consider antibody-independent markers (hemoglobinuria, complement split products).

Critical Care Management: Beyond Steroids

Immediate Stabilization

Temperature control: Maintain ambient temperature >25°C, warm IV fluids
Transfusion strategy: Least incompatible blood if Hb <7 g/dL or symptomatic
Avoid cold exposure: Warm operating rooms, blood warmers, thermal blankets

🚨 Critical Care Pearl: The "Warm Chain"

Maintain patient core temperature >36°C and avoid peripheral cooling. Even brief cold exposure during procedures can trigger massive hemolysis in mixed AIHA.

Pharmacological Management

First-Line Therapy: Modified Steroid Approach

Prednisolone: 1-2 mg/kg/day (higher doses than isolated warm AIHA)
Duration: Minimum 4-6 weeks before tapering
Monitoring: Daily CBC, LDH, bilirubin during acute phase

Second-Line Options: Targeting Dual Pathways

Rituximab (Anti-CD20)

Dosing: 375 mg/m² weekly × 4 doses
Mechanism: B-cell depletion targeting both antibody-producing populations
Evidence: Response rates 60-80% in mixed AIHA⁹
Timing: Consider early in severe cases given delayed onset (6-12 weeks)

Complement Inhibition

Eculizumab: Particularly effective for cold agglutinin component
Dosing: Standard complement inhibition protocol
Monitoring: Complement levels (CH50, C3, C4)
Vaccination: Meningococcal vaccination mandatory¹⁰

Third-Line and Rescue Therapies

Daratumumab (Anti-CD38)

Emerging evidence: Promising in refractory CAD component
Mechanism: Targets plasma cells and complement activation
Dosing: Standard multiple myeloma protocol adapted¹¹

Ibrutinib (BTK Inhibitor)

Rationale: Targets B-cell signaling in both warm and cold antibody production
Evidence: Case series showing sustained responses
Monitoring: Bleeding risk, arrhythmias¹²

🔧 Therapeutic Hack: Sequential Targeting

Start with rituximab for warm component suppression, then add complement inhibition if cold agglutinin activity persists. This sequential approach optimizes response while minimizing toxicity.

Splenectomy Considerations

Limited efficacy in mixed AIHA compared to pure warm AIHA
Reserved for refractory cases with predominant warm component
Timing: After failure of at least two immunosuppressive regimens
Vaccination: Complete vaccination protocol pre-operatively¹³

Monitoring and Complications

Response Assessment Framework

Complete Response

Hemoglobin >11 g/dL
Reticulocyte count <3%
Normal LDH and bilirubin
Negative or significantly reduced DAT

Partial Response

Hemoglobin increase >2 g/dL from baseline
Stable without transfusion support
Reduced hemolytic markers

⚠️ Clinical Oyster: The "Serologic-Clinical Disconnect"

DAT may remain positive for months after clinical remission. Monitor clinical and laboratory parameters rather than DAT conversion for treatment decisions.

Critical Complications

Thromboembolism: Increased risk due to hemolysis and complement activation
Acute kidney injury: From massive intravascular hemolysis
High-output heart failure: From severe chronic anemia
Infection risk: From immunosuppressive therapy
Hypersplenism: From chronic extravascular hemolysis¹⁴

Prognosis and Long-term Management

Factors Influencing Outcome

Underlying disease: Lymphoproliferative disorders associated with worse prognosis
Cold agglutinin titer: Higher titers correlate with treatment resistance
Age: Elderly patients often have more refractory disease
Hemolytic severity: Intravascular component severity predicts complications¹⁵

Long-term Surveillance

Monthly monitoring during active treatment
Quarterly follow-up during maintenance
Annual assessment for underlying malignancy
Vaccination updates if on long-term immunosuppression

Future Directions

Emerging Therapeutic Targets

Complement factor inhibitors: C1s and C5 inhibitors under investigation
Neonatal Fc receptor blockers: Reducing IgG recycling
CAR-T cell therapy: Targeting autoreactive B-cells
Personalized therapy: Based on specific antibody characteristics¹⁶

Precision Medicine Approaches

Genetic profiling: Identifying susceptibility markers
Antibody characterization: Tailoring therapy to specific epitopes
Biomarker development: Predicting treatment response¹⁷

Clinical Pearls and Practical Points

💡 Management Pearls:

Temperature matters: Every aspect of care should consider thermal effects
Early aggressive therapy: Mixed AIHA responds poorly to conservative treatment
Monitor both pathways: Track markers of both intra- and extravascular hemolysis
Consider underlying disease: Most mixed AIHA has an underlying cause

🦪 Clinical Oysters:

Paradoxical cold response: Some patients worsen with rewarming due to increased circulation
Steroid resistance patterns: Cold component often more steroid-resistant than warm
Laboratory artifacts: Cold agglutinins may cause spurious laboratory values
Drug interactions: Cold exposure during surgery can trigger crisis despite anesthesia

🔧 Practical Hacks:

Bedside cold test: Simple cold water challenge can demonstrate temperature sensitivity
Serial thermal amplitude: Track treatment response by measuring antibody activity at increasing temperatures
Warming protocols: Establish institutional protocols for maintaining normothermia
Emergency preparedness: Pre-position blood warmers and thermal blankets in critical areas

Conclusion

Mixed autoimmune hemolytic anemia represents one of the most challenging conditions in critical care hematology. The coexistence of warm AIHA and cold agglutinin disease creates unique pathophysiologic complexity requiring sophisticated diagnostic approaches and nuanced therapeutic strategies. Success depends on recognizing the dual nature of the disease, maintaining thermal homeostasis, and employing targeted immunotherapy that addresses both warm antibody-mediated extravascular hemolysis and cold agglutinin-induced complement activation.

The rarity of this condition demands a high index of suspicion and multidisciplinary collaboration between critical care physicians, hematologists, and transfusion medicine specialists. As our understanding of B-cell biology and complement pathways continues to evolve, newer targeted therapies offer hope for improved outcomes in this challenging patient population.

Early recognition, aggressive immunosuppression, and meticulous supportive care remain the cornerstones of management, while emerging therapies targeting specific pathophysiologic pathways promise to transform outcomes for patients with this rare but serious condition.

References

Lechner K, Jäger U. How I treat autoimmune hemolytic anemias in adults. Blood. 2010;116(11):1831-1838.
Barcellini W, Fattizzo B. Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia. Dis Markers. 2015;2015:635670.
Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648.
Garratty G. The significance of IgG on the red cell surface. Transfus Med Rev. 1987;1(1):47-57.
Berentsen S, Randen U, Tjønnfjord GE. Cold agglutinin-mediated autoimmune hemolytic anemia. Hematol Oncol Clin North Am. 2015;29(3):455-471.
Packman CH. Hemolytic anemia due to warm autoantibodies. Blood Rev. 2008;22(1):17-31.
Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114-1121.
Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis: mixed warm and cold antibody type. Acta Haematol. 1983;69(4):266-274.
Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101(10):3857-3861.
Röth A, Bommer M, Hüttmann A, et al. Eculizumab in cold agglutinin disease: a final analysis of the DECADE study. Blood. 2018;132(Suppl 1):1464.
Oosterveld M, Garssen J, den Hartog Y, et al. Daratumumab in cold agglutinin disease. N Engl J Med. 2020;383(14):1389-1391.
Tiede MP, Czerwinski DK, Berry GJ, et al. Fatal acute hemolysis: an unusual initial presentation of chronic lymphocytic leukemia. Am J Hematol. 2004;77(4):355-357.
Dierickx D, Verhoef G, Van Hoof A, et al. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med. 2009;266(5):484-491.
Bass GF, Tuscano ET, Tuscano JM. Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev. 2014;13(4-5):394-400.
Berentsen S. Cold agglutinin disease. Hematology Am Soc Hematol Educ Program. 2016;2016(1):226-231.
Maura F, Curti A, Lascialfari L, et al. Monoclonal gammopathy of undetermined significance and the spectrum of plasma cell disorders: updated criteria and management recommendations. Clin Adv Hematol Oncol. 2013;11(8):488-501.
Hill QA, Stamps R, Massey E, et al. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017;177(2):208-220.

Adult Still's Disease

Adult Still's Disease Presenting in the Intensive Care Unit: Recognition, Diagnosis, and Management Challenges

Dr Neeraj Manikath,Claude.ai

Abstract

Adult-onset Still's disease (AOSD) is a rare systemic inflammatory disorder that can present with life-threatening complications requiring intensive care unit (ICU) admission. The classic triad of high-spiking fever, arthralgia, and salmon-pink rash is often accompanied by hyperferritinemia, making differentiation from sepsis, hemophagocytic lymphohistiocytosis (HLH), and other hyperinflammatory syndromes challenging. This review examines the clinical presentation, diagnostic approach, and management of AOSD in critically ill patients, highlighting key diagnostic pearls and common pitfalls encountered in the ICU setting.

Keywords: Adult Still's disease, hyperferritinemia, intensive care, systemic inflammation, fever of unknown origin

Introduction

Adult-onset Still's disease (AOSD) is a rare systemic inflammatory disorder with an estimated annual incidence of 0.16-0.4 per 100,000 adults.¹ While most cases present with classic outpatient symptoms, approximately 15-20% of patients require ICU admission due to severe systemic complications.² The diagnosis becomes particularly challenging in the ICU setting, where the differential diagnosis includes sepsis, malignancy-associated fever, and other hyperinflammatory syndromes.

The condition was first described by Eric Bywaters in 1971 as the adult counterpart to systemic juvenile idiopathic arthritis (sJIA).³ Despite decades of research, AOSD remains a diagnosis of exclusion with no pathognomonic laboratory test or histological finding.

Clinical Presentation in the ICU

Pearl #1: The "Quotidian Fever" Pattern

The pathognomonic fever pattern in AOSD is quotidian (daily) with temperature spikes reaching 39-40°C, typically occurring in late afternoon or evening, followed by rapid defervescence to normal or subnormal temperatures.⁴ This pattern, when present, is highly suggestive of AOSD and differs from the sustained fever patterns commonly seen in sepsis.

Classic Manifestations

Systemic Features:

High-spiking fever (>39°C) - present in 95% of patients
Arthralgia/arthritis affecting knees, wrists, and ankles - 90%
Characteristic salmon-pink, evanescent rash - 85%
Sore throat (often the initial symptom) - 70%
Lymphadenopathy - 65%
Hepatosplenomegaly - 60%

Oyster #1: The Disappearing Rash

The salmon-pink, maculopapular rash of AOSD is notoriously evanescent, appearing with fever spikes and disappearing during afebrile periods. In the ICU, this rash may be missed during routine examinations if not specifically sought during febrile episodes. The rash demonstrates Koebner's phenomenon (appearing at sites of skin trauma) and is typically non-pruritic.⁵

Life-Threatening Complications Requiring ICU Care

1. Macrophage Activation Syndrome (MAS)

Occurs in 10-15% of AOSD patients
Presents with persistent fever, cytopenias, coagulopathy
Mortality rate: 10-20%⁶

2. Acute Respiratory Distress Syndrome (ARDS)

Pulmonary involvement in 20-30% of severe cases
May present as acute pneumonitis or pleural effusions
Often steroid-responsive⁷

3. Cardiac Complications

Pericarditis (30-40% of cases)
Myocarditis (rare but potentially fatal)
Tamponade requiring immediate intervention⁸

4. Hepatic Dysfunction

Acute hepatitis with transaminase elevation >1000 IU/L
Fulminant hepatic failure (rare)
Drug-induced liver injury from NSAIDs⁹

Laboratory Findings

Pearl #2: The Hyperferritinemia Clue

Serum ferritin levels are markedly elevated in AOSD, often exceeding 3000 ng/mL (normal: 15-300 ng/mL). More importantly, the glycosylated ferritin fraction is typically <20% in AOSD, compared to >50% in infectious or malignant causes of hyperferritinemia.¹⁰

Key Laboratory Parameters

Inflammatory Markers:

ESR: typically >100 mm/hr
CRP: markedly elevated (>100 mg/L)
Leucocytosis: 15,000-20,000/μL with neutrophil predominance
Thrombocytosis: common in active disease

Liver Function:

Transaminase elevation (ALT/AST 2-5x normal)
Elevated alkaline phosphatase and bilirubin
Hypoalbuminemia

Negative Studies:

Rheumatoid factor: negative
ANA: negative (low-titer positive in <10%)
Blood cultures: persistently negative

Hack #1: The Ferritin-to-ESR Ratio

A practical bedside calculation: Ferritin (ng/mL) ÷ ESR (mm/hr) ratio >21.5 has 79% sensitivity and 46% specificity for AOSD diagnosis.¹¹ While not diagnostic, this simple calculation can raise suspicion in febrile ICU patients.

Diagnostic Criteria and Challenges

Yamaguchi Criteria (1992) - Most Widely Used

Major Criteria:

Fever ≥39°C lasting ≥1 week
Arthralgia/arthritis ≥2 weeks
Typical rash
Leucocytosis ≥10,000/μL with ≥80% neutrophils

Minor Criteria:

Sore throat
Lymphadenopathy/splenomegaly
Liver dysfunction
Negative RF and ANA

Diagnosis requires: ≥5 criteria including ≥2 major criteria, plus exclusion of infections, malignancies, and other rheumatic diseases.¹²

Pearl #3: The "Exclusion Diagnosis" Challenge

AOSD remains a diagnosis of exclusion. In the ICU setting, this requires systematic evaluation for:

Bacterial, viral, and fungal infections
Hematologic malignancies (especially lymphoma)
Autoimmune diseases (SLE, vasculitis)
Drug-induced fever
Hemophagocytic lymphohistiocytosis

Oyster #2: AOSD vs. Sepsis Differentiation

Distinguishing AOSD from sepsis in critically ill patients is challenging. Key differentiating features:

Feature	AOSD	Sepsis
Fever pattern	Quotidian, spiking	Sustained or irregular
Rash	Salmon-pink, evanescent	Variable, often petechial
Sore throat	Non-exudative, prominent	Usually absent
Ferritin	>3000 ng/mL, low glycosylation	Elevated but <3000 ng/mL
Procalcitonin	Normal or mildly elevated	Markedly elevated
Blood cultures	Negative	Often positive

Advanced Diagnostic Modalities

Hack #2: The 18F-FDG PET-CT Advantage

18F-FDG PET-CT shows characteristic patterns in AOSD:

Diffuse bone marrow uptake
Splenic uptake
Lymph node involvement
Joint inflammation
Absence of focal infectious foci¹³

This imaging modality is particularly valuable when differentiating AOSD from occult malignancy or infection.

Biomarkers Under Investigation

IL-18 and IL-1β:

Markedly elevated in active AOSD
May correlate with disease activity
Not yet in routine clinical use¹⁴

S100A8/A9 (Calprotectin):

Elevated in active disease
May predict treatment response
Commercially available assays emerging¹⁵

Management in the ICU Setting

Pearl #4: The Steroid Response Test

A dramatic response to corticosteroids within 24-48 hours is characteristic of AOSD. This "therapeutic trial" can be both diagnostic and therapeutic, but should only be undertaken after excluding active infection.¹⁶

First-Line Treatment

Corticosteroids:

Prednisolone 0.5-1.0 mg/kg/day
Higher doses (1-2 mg/kg/day) for severe complications
IV methylprednisolone for critically ill patients
Expect rapid improvement in fever and symptoms¹⁷

NSAIDs:

Limited utility in ICU patients due to organ dysfunction
Naproxen 500 mg BID or indomethacin 150 mg/day
Avoid in renal dysfunction or bleeding risk

Hack #3: The "Bridge Therapy" Approach

For critically ill patients where infection cannot be completely excluded:

Start broad-spectrum antibiotics
Simultaneously begin moderate-dose steroids (0.5 mg/kg prednisolone)
Monitor response over 48-72 hours
Discontinue antibiotics if cultures negative and steroid response confirms AOSD

Second-Line and Biologic Therapies

Methotrexate:

15-20 mg weekly
Steroid-sparing agent
Monitor for hepatotoxicity¹⁸

IL-1 Inhibitors (Anakinra):

100 mg subcutaneous daily
Particularly effective for refractory cases
Rapid onset of action (24-48 hours)
Preferred for MAS complication¹⁹

IL-6 Inhibitors (Tocilizumab):

8 mg/kg IV monthly
Alternative for anakinra-refractory cases
Monitor for infections²⁰

TNF-α Inhibitors:

Reserved for refractory arthritis
Less effective for systemic features
Higher infection risk in ICU patients²¹

Pearl #5: Managing Macrophage Activation Syndrome

MAS is the most feared complication of AOSD. Management principles:

High-dose corticosteroids (methylprednisolone 10-30 mg/kg)
Early IL-1 inhibition with anakinra
Consider etoposide for refractory cases
Cyclosporine as alternative immunosuppression
Avoid biologics that may worsen cytokine storm²²

Prognosis and Long-term Outcomes

Disease Patterns

Monocyclic (30-40%):

Single episode lasting <1 year
Complete remission possible
Best prognosis

Polycyclic (25-30%):

Recurrent flares with intervening remissions
May evolve to chronic arthritis
Intermediate prognosis

Chronic Articular (30-40%):

Persistent arthritis with minimal systemic features
Joint destruction possible
Requires long-term management²³

Oyster #3: The Transformation Phenomenon

AOSD can evolve over time, with initial systemic features giving way to chronic arthritis resembling rheumatoid arthritis. This transformation affects treatment strategies and long-term prognosis.

ICU-Specific Prognostic Factors

Favorable:

Early diagnosis and treatment
Good steroid response
Absence of MAS
Monocyclic pattern

Unfavorable:

Delayed diagnosis (>3 months)
MAS development
Requirement for mechanical ventilation
Multi-organ failure²⁴

Special Considerations in ICU Management

Hack #4: The Infection Monitoring Protocol

AOSD patients on immunosuppression require enhanced infection surveillance:

Daily procalcitonin monitoring
Serial blood cultures
Fungal biomarkers (galactomannan, β-D-glucan)
CMV/EBV monitoring
Prophylactic antimicrobials in high-risk patients²⁵

Drug Interactions and Complications

Steroid-Related:

Hyperglycemia requiring insulin protocols
Increased infection risk
Peptic ulcer prophylaxis
Psychiatric complications

Biologic-Related:

Immunosuppression
Reactivation of latent infections
Infusion reactions
Cytopenias²⁶

Future Directions and Emerging Therapies

Novel Therapeutic Targets

JAK Inhibitors:

Tofacitinib and baricitinib showing promise
Oral administration advantage
Rapid onset of action²⁷

IL-18 Inhibition:

Tadekinig alfa under investigation
Targets key cytokine in AOSD pathogenesis
Early trials promising²⁸

Precision Medicine Approaches

Genetic Markers:

HLA associations being defined
Pharmacogenomics for drug selection
Personalized treatment algorithms²⁹

Biomarker-Guided Therapy:

IL-18 levels for treatment monitoring
Ferritin kinetics for response assessment
Cytokine profiles for drug selection³⁰

Clinical Pearls Summary

Quotidian fever pattern with afternoon/evening spikes is pathognomonic
Hyperferritinemia >3000 ng/mL with low glycosylated fraction suggests AOSD
Evanescent salmon-pink rash appears with fever and demonstrates Koebner phenomenon
Dramatic steroid response within 24-48 hours supports diagnosis
MAS development requires immediate aggressive immunosuppression

Take-Home Messages for ICU Practitioners

Maintain high index of suspicion in young adults with fever of unknown origin
Systematic exclusion of infections and malignancy remains crucial
Early diagnosis and treatment improve outcomes significantly
Steroid therapy should be initiated promptly once infection is excluded
IL-1 inhibitors are game-changers for refractory cases and MAS
Long-term rheumatologic follow-up is essential for all patients

References

Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still's disease. Autoimmun Rev. 2014;13(7):708-722.
Rau M, Schiller M, Krienke S, et al. Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis. J Rheumatol. 2010;37(11):2369-2376.
Bywaters EG. Still's disease in the adult. Ann Rheum Dis. 1971;30(2):121-133.
Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine. 1991;70(2):118-136.
Ota T, Higashi S, Suzuki H, et al. Increased serum ferritin levels in adult Still's disease. Lancet. 1987;1(8528):562-563.
Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503-1516.
Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol. 2004;31(11):2189-2198.
Franchini S, Dagna L, Salvo F, et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. Arthritis Rheum. 2010;62(8):2530-2535.
Girard C, Rech J, Brown M, et al. Elevated serum levels of free interleukin-18 in adult-onset Still's disease. Rheumatology. 2016;55(12):2237-2247.
Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset Still's disease. Medicine. 2002;81(3):194-200.
Hu QY, Zeng T, Sun CY, et al. Clinical features and current treatments of adult-onset Still's disease: a multicentre survey of 517 patients in China. Clin Exp Rheumatol. 2019;37(4):52-57.
Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;19(3):424-430.
Yamashita H, Kubota K, Takahashi Y, et al. Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active adult-onset Still's disease. Rheumatology. 2012;51(11):2013-2019.
Colafrancesco S, Priori R, Alessandri C, et al. IL-18 serum level in adult onset Still's disease: a marker of disease activity. Int J Inflam. 2012;2012:156890.
Frosch M, Strey A, Vogl T, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000;43(3):628-637.
Jamilloux Y, Gerfaud-Valentin M, Martinon F, et al. Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. Immunol Res. 2015;61(1-2):53-62.
Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis. 2006;65(5):564-572.
Fautrel B, Borget C, Rozenberg S, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol. 1999;26(2):373-378.
Fitzgerald AA, Leclercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005;52(6):1794-1803.
Puéchal X, DeBandt M, Berthelot JM, et al. Tocilizumab in refractory adult Still's disease. Arthritis Care Res. 2011;63(1):155-159.
Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum. 2002;46(5):1171-1176.
Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 2014;28(2):277-292.
Cush JJ, Medsger TA Jr, Christy WC, et al. Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum. 1987;30(2):186-194.
Kim YJ, Koo BS, Kim YG, et al. Clinical features and prognosis in 82 patients with adult-onset Still's disease. Clin Exp Rheumatol. 2014;32(1):28-33.
Ruscitti P, Cipriani P, Masedu F, et al. Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14:194.
Nordström D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J Rheumatol. 2012;39(10):2008-2011.
Gabay C, Fautrel B, Rech J, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. Ann Rheum Dis. 2018;77(6):840-847.
Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018;77(12):1720-1729.
Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine. 2013;61(2):345-348.
Put K, Avau A, Brisse E, et al. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ. Rheumatology. 2015;54(8):1507-1517.